Indiana University

Gachon University of Industry—academic Cooperation

Gachon University of Industry-Academic Cooperation Foundation

Timothy William Corson

Seung-Yong Seo

Bit Lee

Halesha Basavarajappa

Xiang Fei

Mark R Kelley

Rania Sulaiman

Kamakshi Sishtla

Halesha D Basavarajappa

The invention relates to a method of treatment of a patient with a ferrochelatase inhibitor, or a pharmaceutically acceptable salt thereof, or a derivative thereof. Also, the invention relates to a method of treatment of a patient with a ferrochelatase inhibitor that is a triazolopyrimidinone, or a derivative thereof, or a pharmaceutically acceptable salt thereof.

Ferrochelatase inhibitors and methods of use

[[(2E)-2-[(3-methoxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methylidene]-N,N-diethylpentanamide] (APX2009) and (2E)-2-[(3-methoxy-1,4-dioxo-1,4-dihydronapthalen-2-yl)methylidene]-N-methoxypentanamide] (APX2014) for inhibiting ocular diseases are disclosed herein.

Targeting ocular diseases with novel APE1/Ref-1 inhibitors

Compositions including the combination of cremastranone analogs and anti-angiogenic agents and the use of the compositions for targeting ocular angiogenesis such as seen in neovascular eye diseases are disclosed.

Composition for blocking angiogenesis

Methods for treating angiogenesis-mediated diseases are disclosed. More particularly, the present disclosure relates to methods of inhibiting ferrochelatase as an antiangiogenic therapy.

Inhibition of ferrochelatase as an antiangiogenic therapy

Synthetic cremastranone and cremastranone analogs are disclosed. Additionally, methods for synthesizing cremastranone and cremastranone analogs are disclosed. Methods of treating ocular neovascularization disorders and treating angiogenesis-mediated disease are also disclosed.

Growing community of inventors

Fishers, IN, United States of America

Timothy William Corson